Showing 2681-2690 of 3890 results for "".
The Role of Hypnosis in Dermatology: More than Mere Suggestion
https://practicaldermatology.com/columns/clinical-focus-1/the-role-of-hypnosis-in-dermatology-more-than-mere-suggestion/23240/Hypnosis has shown promising results for patients who have had difficulty responding to more conventional therapies.Diagnosing and Managing Hair Disorders
https://practicaldermatology.com/topics/general-topics/diagnosing-and-managing-hair-disorders/20624/From loss to overgrowth, hair disorders may be associated with systemic causes.Turmeric, Curcumin, and Curcuminoids: A Dermatologic Review
https://practicaldermatology.com/columns/clinical-focus-1/turmeric-curcumin-and-curcuminoids-a-dermatologic-review/23377/Curcumin, one of the active compounds of turmeric, exhibits anti-inflammatory, antimicrobial, antioxidant, anti-nociceptive, and antineoplastic properties.Cutaneous T-Cell Lymphoma: Mogamulizumab as a Novel Treatment for Refractory Mycosis Fungoides and Sezary Syndrome
https://practicaldermatology.com/youngmd-connect/resident-resource-center/Cutaneous-T-Cell-Lymphoma-Mogamulizumab-as-a-Novel-Treatment-for-Refractory-Mycosis-Fungoides-and-Sezary-Syndrome/23409/An overview of the diagnosis and prognosis of CTCL.Choosing the Best Medical Website Provider
https://practicaldermatology.com/topics/practice-management/choosing-the-best-medical-website-provider/22967/Biologics for Psoriasis: A Status Update
https://practicaldermatology.com/topics/psoriasis/biologics-for-psoriasis-a-status-update/23006/The field has grown substantially from the early 2000s to include now a dozen innovator systemic agents, a host of biosimilars, and soon JAK Inhibitors.The Role of GLP-1RAs in Treating Inflammatory Dermatologic Diseases
https://practicaldermatology.com/issues/novemberdecember-2025/the-role-of-glp-1ras-in-treating-inflammatory-dermatologic-diseases/48899/Herein, we review the benefits and risks of GLP-1RAs with a focus on these 3 chronic inflammatory conditions.Complications of Biologic Therapy for Psoriasis: Part II
https://practicaldermatology.com/topics/psoriasis/complications-of-biologic-therapy-for-psoriasis-part-ii/22039/Therapeutic success requires clinicians to understand emerging and established safety concerns.- Dr. Jacob Chacko Joins Bonti's Board of Directorshttps://practicaldermatology.com/news/dr-jacob-chacko-joins-bontis-board-of-directors/2457893/Jacob Chacko, MD has joined Bonti’s Board of Directors. Dr. Chacko has served as the Chief Financial Officer of Ignyta, Inc. since May 2014. At Ignyta, he leads multiple functions, including Finance, Accounting, Investor Relations, Communications
- Study: Test Improves the Risk Stratification of Patients with Stage I Melanomahttps://practicaldermatology.com/news/study-finds-decisiondx-melanoma-significantly-improves-the-risk-stratification-of-patients-with-stage-i-melanoma-compared-to-american-joint-committee-on-cancer-8th-edition-staging/2462252/Results from a recent study showed the potential of a 31-gene expression profile (31-GEP) test in improving the prognosis for patients diagnosed with stage I cutaneous melanoma. Despite being considered at low risk for metastasis or melanoma-specific death, patients with stage I cutaneous